Efficacy and safety of haemodialysis treatment with the Hemocontrol™ biofeedback system: a prospective medium‐term study

Abstract

HBS treatment is effective in lowering hypovolaemia-associated morbidity compared with BD treatment; this could be related to a greater ECV stability. Furthermore, HBS is a safe treatment in the medium-term because these results are not achieved through potentially harmful changes in blood pressure, body weight, and serum sodium concentration.